Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 67

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 67
---
 inventory of mass-produced
product to satisfy demands for any of our product candidates. Our clinical supply will also be limited to small quantities and any latent
defects discovered in our supply could significantly delay our development timelines.

<div align='center'>32</div>

In addition, our actual
and potential future reliance on a limited number of third-party manufacturers exposes us to the following risks:

| ● | We may be unable to identify                                                                                                          
 manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions   
 regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would 
 have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, 
 if any.                                                                                                                               |

| ● | Our third-party manufacturers                                                                                                     
 might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical 
 and commercial needs, if any.                                                                                                     |

| ● | Contract manufacturers                                                 
 may not be able to execute our manufacturing procedures appropriately. |

| ● | Manufacturers are subject                                                                                                                 
 to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure     
 strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party 
 manufacturers’ compliance with these regulations and standards.                                                                           |

| ● | We may not own, or may                                                                                                                 
 have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process 
 for our products.                                                                                                                      |

| ● | Our future contract manufacturers                                                                                                      
 may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials 
 or to successfully produce, store and distribute our products.                                                                         |

| ● | Our third-party manufacturers                      
 could breach or terminate their agreement with us. |

Our contract manufacturers
would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Our current and
potential future CDMOs may also be required to shut down in response to the spread of health epidemics or pandemics, or they may prioritize
manufacturing for therapies or vaccines for other diseases. In addition, our CDMOs have certain responsibilities for storage of raw materials
and in the past have lost or failed to adequately store our raw materials. We will also rely on third parties to store our released product
candidates